Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses a hair loss treatment regimen including oral dutasteride, oral minoxidil, tadalafil, and the recent addition of RU58841. The user shares experiences with these treatments, noting significant hair regrowth and stabilization, and discusses the cost and preparation of RU58841.

Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.

The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

Men discussing hair loss treatments, including bicalutamide, cyproterone acetate, dutasteride, minoxidil, and RU58841. They share experiences and concerns about side effects like infertility, liver health, and feminization.

The user mixes their own RU58841 solution and found that increasing the ethanol content improved absorption and reduced scalp itching. A study on minoxidil showed that penetration increased with higher ethanol concentrations, reaching maximum penetration at 90% ethanol.

The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.

The user started a hair care routine using 0.5mg finasteride daily, 2ml of 5% minoxidil, and 4.5mg of cetirizine topically to address hair loss. They plan to provide updates and are also interested in cetirizine's potential to reduce scalp itching and redness due to its anti-inflammatory properties.

Combining dutasteride and an aromatase inhibitor may increase testosterone levels significantly, potentially enhancing athletic performance but also posing health risks like elevated blood pressure and worsened cholesterol. The user is experimenting with dutasteride, anastrozole, minoxidil, and ketoconazole shampoo to manage hair loss and estradiol levels, while monitoring side effects and hormone levels.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

Clascoterone is suggested as an alternative for those who experience side effects from finasteride and dutasteride. It is not widely available yet, but some users are obtaining it from compounding pharmacies or suppliers like Echemi.

RU58841 was the only treatment that slowed hair loss and reduced irritation for a DUPA sufferer after trying finasteride, minoxidil, and dutasteride with no success. The user continues using 6mg oral minoxidil, 0.5mg dutasteride, and an 8% RU58841 solution.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.

User experienced slow gains with topical fin+min, switched to topical dut+min, and considered adding Eucapil. Another user suggested DUT may be less effective topically due to high molar mass and mentioned Fluridil as a weak anti-androgen that could help.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.

Dutasteride may inhibit androgen receptors in addition to reducing DHT, potentially explaining its effectiveness over finasteride for hair loss. Concerns about its impact on muscle growth are debated, with some suggesting no significant effects.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

Hair loss treatments, specifically the use of Alfatradiol as an over-the-counter topical 5AR inhibitor that has been shown to be effective in stopping hair loss without side effects. Other treatments discussed include Minoxidil, finasteride and RU58841.

Discussing and researching different treatments for hair loss, including RU58841, Dutasteride, Spironolactone, Retin-A, Stemoxydine (Neogenic), Copper peptides, Superoxide Dismutase, NANO, and Eucapil.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

A user with seborrheic dermatitis uses Ketoconazole 2% and Betamethasone and is considering starting Minoxidil for thinning hair. They are concerned about using Minoxidil and Betamethasone simultaneously.

The user is considering adding Pyrilutamide or Alfatradiol as a topical treatment for hair loss after oral Finasteride and Dutasteride became less effective. Other users suggest Pyrilutamide for its safety profile, while one user shares positive experiences with RU58841 for reducing scalp itch and improving hairline.

The user is considering switching to oral dutasteride, topical minoxidil, retinoic acid, and clobetasol for hair loss treatment, after limited regrowth with finasteride and other topicals. They are seeking a source for clobetasol, as they believe it may help with their condition.

BionicBell discussed using Bimatoprost, a medication typically for eyelash growth, for hair loss and mentioned a compounding pharmacy that can mix it with other ingredients like minoxidil and finasteride. They are seeking advice on using topical finasteride for female pattern baldness and are considering a custom foam combination to maximize hair growth results.

The user has not seen results from various hair loss treatments including finasteride, dutasteride, minoxidil, and others over several years and is considering adding RU58841 and starting hormone replacement therapy. They are also experiencing anxiety and contemplating moving to a more accepting environment for their nonbinary identity.